Photo taken from dreamstime.com
Jul 7, 2024, 07:19
Adjuvant GemCis vs CRT with capecitabine in gallbladder cancer
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X:
“Adjuvant GemCis (gemcitabine and cisplatin) vs CRT (chemoradiotherapy) with capecitabine in gallbladder cancer GECCOR-GB study in JAMA Oncology.
Phase II
Resected stage II/III
- R0 or R1 1-year DFS: %88.9 vs 77.8%
- 2-year DFS: 74.8% vs 74.8%
- Completion of planned trratment: 82% vs 62%
- Both met primary endpoint of 1-y DFS 77%“
Proceed to the study.
Source: Erman Akkus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48